Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis

Table 2 Albumin, total bilirubin, prothrombin times, and model for end-stage liver disease values during follow-up

Time point	Studies (n)	Cases (n)	Type of model	I2	P value	Estimate	95%CI
Change from baseline of albumin levels (g/L)
8 wk	2	9	RE	0.000	0.969	-0.28	-3.31-2.85
16 wk	2	13	RE	0.000	0.995	2.60	-0.35-5.56
24 wk	3	13	RE	0.413	0.185	5.28	1.81-8.75
48 wk	2	14	RE	0.831	0.015	4.39	-1.62-10.40
Change from baseline of ALT levels (IU/L)
4 wk	2	16	RE	0.667	0.083	-16.33	-50.71-18.06
24 wk	3	13	RE	0.647	0.059	-7.04	-33.99-19.91
48 wk	2	10	RE	0.333	0.221	-18.18	-44.03-7.06
Change from baseline of TBIL levels
4 wk	2	16	RE	0.948	0.000	-69.34	-191.12-53.45
24 wk	3	13	RE	0.945	0.000	-47.21	-130.18-35.76
48 wk	2	10	RE	0.966	0.000	-86.17	-254.53-82.19
Change from baseline of PT values (s)
24 wk	3	13	RE	0.843	0.002	-4.77	-9.22--0.33
48 wk	2	10	RE	0.931	0.000	-5.88	-13.42-1.65
Change from baseline MELD scores
2 wk	2	26	RE	0.977	0.000	-3.27	-8.84-2.30
4 wk	2	26	RE	0.994	0.000	-6.28	-17.86-5.29
8 wk	2	23	RE	0.606	0.111	-1.43	-4.92-2.06
16 wk	2	23	RE	0.000	0.644	0.31	-0.67-1.30
24 wk	4	33	RE	0.982	0.000	-4.28	-13.39-4.83
48 wk	2	10	RE	0.948	0.000	-7.62	-16.86-1.63

PT: Prothrombin times; MELD: Model for end-stage liver disease; TBIL: Total bilirubin; ALT: Alanine aminotransferase; RE: Random effects.